Summary of the Conference Call for Yijiahe Group Company Overview - Yijiahe Group operates through its subsidiary Tuodao Medical, focusing on brain-computer interface (BCI) technology and surgical robotics, with applications in healthcare and industrial sectors [2][3] Core Business Segments - The company’s business includes energy, surgical robots, commercial cleaning, and military humanoid robots [2][3] - Tuodao Medical is developing automated implantation technology for invasive BCIs and surgical robots, aiming to enhance the quality of life for individuals and expand applications in various work environments [2][3] Technological Accumulation - Tuodao Medical has made significant advancements in: 1. **Invasive Brain-Computer Interfaces**: Capable of capturing high-precision electrophysiological signals for complex control [5] 2. **Stereotactic Technology**: Transitioning from traditional frameworks to surgical robots to improve precision and reduce errors [5] 3. **Development of Domestic Surgical Robots**: Companies like Huazhi Weichuang and Baihui Yikang have introduced new products, expanding the range of applications and improving clinical outcomes [5][6] 4. **Application Processes**: Emphasizing precise positioning during invasive electrode implantation to minimize trauma and enhance success rates [5] Market Dynamics - The domestic market for neurosurgical robots is rapidly evolving, with leading companies like Huazhi Weichuang and Baihui Yikang replacing imported products, indicating strong domestic competitiveness [6] - The market has seen a shift from larger, complex systems to more compact and stable solutions, reflecting changing clinical needs [9] Importance of Surgical Robots - Surgical robots are essential for BCI procedures due to the complexity of the human brain, providing personalized solutions and overcoming limitations of manual operations [7] Development History - The introduction of ROSA in 2014 marked the beginning of neurosurgical robots in China, but adoption was slow due to operational complexities. Recent years have seen a surge in new entrants and technological advancements [8][9] Key Considerations for BCI Implantation - Successful BCI implantation requires careful consideration of imaging analysis, multimodal image fusion, robotic navigation, and automated execution mechanisms [10] Competitive Advantages - Tuodao Medical's comprehensive product line and integration of advanced technologies like force feedback provide a competitive edge in the neurosurgery and BCI sectors [15] Future Outlook - The BCI industry is expected to grow rapidly, with automation being a prerequisite for mass production. The company is closely monitoring market trends and planning accordingly [16][17] - The timeline for widespread adoption remains uncertain, but the company is preparing for future developments in automated surgical procedures [16][17]

Q&A 脑机接口产业目前的市场行情如何？有哪些关键因素推动了这一领域的发展？ 最近脑机接口市场行情非常火爆，主要是由于国内出台了利好政策，以及马斯 克在社交媒体上表示 Neuralink 将在 2026 年大规模生产脑机接口设备。这些 因素共同引爆了整个板块的情绪。脑机接口产业的发展关键在于快速商业化落 地，尤其是在非侵入式领域，企业需要具备强大的销售渠道能力、品牌力以及 与原有医疗业务的协同效应，以促进商业化落地速度和后续发展。 脑机接口产业更新及重点标的推荐 20260106 摘要 脑机接口产业正快速发展，商业化落地是关键，尤其在非侵入式领域， 企业需具备强大的销售渠道、品牌力及与原有医疗业务的协同效应，以 加速商业化进程。预计到 2025 年全球市场规模将达 30 亿美元，医疗 端应用将在 2030 年超过 400 亿美元。 脑机接口技术路径包括侵入式、半侵入式和非侵入式。侵入式信号质量 高但风险大，适用于重症患者；非侵入式安全性高，商业化快但竞争激 烈；半侵入式介于两者之间。美国企业多布局半侵入式，中国企业则以 非侵入式为主。 Neuralink 在侵入式脑机接口领域领先，已完成约 20 例人体植入， ...

Summary of Neural Interface Technology Conference Industry Overview - The conference focused on the neural interface technology industry, particularly advancements made by Neuralink and domestic companies in China [1][3][4][5][10]. Key Points and Arguments Neuralink's Advancements - Neuralink has significantly reduced the cost of implantable devices, with fixture costs dropping by 95%, from approximately $5,000-$6,000 to a few hundred dollars [1][3][4]. - The electrode production cost remains high, at over $10,000 per electrode, but the implantation speed has improved from 20 seconds to 1.5 seconds per electrode, facilitating clinical applications [1][3][4]. - The company has entered clinical trials, utilizing BlackRock electrodes and developing its own implantation devices that combine electron microscopy and OCR systems for precise electrode placement [1][8][9]. Challenges in Neural Interface Technology - The industry faces challenges such as complex electrode production processes, low yield rates, and patent barriers, particularly regarding non-invasive puncture techniques patented by Musk [1][5][6]. - Domestic companies need breakthroughs in materials, processes, and patent strategies to compete effectively [1][5]. Comparison of Invasive and Semi-Invasive Techniques - Neuralink's fully invasive technology targets complex diseases, while domestic companies like BoruiKang focus on semi-invasive methods primarily for rehabilitation, which are less risky and costly [1][7][10]. - The main difference lies in the application: fully invasive techniques aim to treat severe conditions through deep neural stimulation, whereas semi-invasive methods are used for rehabilitation by repairing damaged nerves [1][7]. Domestic Industry Landscape - Domestic companies such as JieTi, Tiger Technology, and WeiLing have made progress in flexible electrodes but still lag behind international leaders like Neuralink in terms of channel count (128 channels vs. Neuralink's 1,024 channels) and other technical specifications [1][10]. - The downstream applications of the domestic neural interface industry account for 70% of the market share, focusing on rehabilitation devices and commercial products, while upstream investments in electrode and chip development are capital-intensive [1][10]. Clinical Applications and Future Directions - BoruiKang's semi-quantitative methods have been widely adopted in over 20 hospitals in China, with more than 200 clinical trials conducted in 2024 [12]. - The potential for interventionist neural interfaces is highlighted, with successful trials indicating a promising future if challenges like vascular blockage can be addressed [2][16]. Competitive Landscape - Companies like Medtronic have received FDA approval for their brain stimulators, showing significant efficacy in treating conditions like epilepsy, while competitors like Pinchi Medical face challenges due to patent restrictions [14][25]. - The market for deep brain stimulation (DBS) devices is still developing, with no fully mature embedded products available yet [25]. Additional Important Insights - The domestic neural interface industry is characterized by a high investment threshold in the upstream sector, with a typical investment ratio of 3:1 or 4:1 favoring downstream applications [10]. - The technology's application in treating neurological diseases is expanding, with potential uses in conditions like Alzheimer's and depression through adaptive neural regulation [19]. This summary encapsulates the key discussions and insights from the neural interface technology conference, highlighting both advancements and challenges within the industry.

Core Insights - The brain-computer interface (BCI) sector is experiencing significant growth, highlighted by the recent completion of approximately 2 billion yuan financing by Qiangnao Technology, marking it as the second-largest financing in the field globally, after Neuralink [1][2] Industry Overview - The BCI sector has become the hottest investment track in the A-share market since the beginning of 2026, with multiple stocks such as Innovation Medical, Aipeng Medical, and Xiangyu Medical achieving consecutive trading limits [1] - The industry is currently driven by both policy support and technological breakthroughs, with expectations for Neuralink's large-scale production and automated surgical solutions marking a transition from clinical validation to commercial viability [3] Company Highlights - Qiangnao Technology, founded in February 2015, focuses on non-invasive BCI technology and has received FDA and CE certifications, making it one of the largest investors in BCI R&D globally [2] - The company has launched several products, including smart bionic limbs and brain-machine intelligent sleep devices, and has been recognized by TIME magazine as one of the best inventions of the year [2] Recent Developments - On January 6, multiple BCI stocks, including Sanbo Brain Science and Maillande, issued announcements regarding abnormal trading fluctuations, warning investors of potential risks [4][5][6] - Sanbo Brain Science, while experiencing significant stock price increases, clarified that it does not engage in BCI product development, and its revenue from neuro-regulation technology is minimal [4] - Maillande and Xiangyu Medical also reported that their BCI products are still in the R&D phase and have not yet achieved significant sales impact [5][6]

Core Viewpoint - The A-share market has seen a significant pullback in several brain-computer interface (BCI) concept stocks, with notable declines among various companies [1] Group 1: Stock Performance - Companies such as 麦澜德 (Mikland) and 熵基科技 (Entropy Technology) experienced declines exceeding 10% [1] - 诚益通 (Chengyi Tong) and 雷迪克 (Redik) fell over 7% [1] - 博拓生物 (Botuo Bio) and 爱朋医疗 (Aipeng Medical) dropped more than 6% [1] - 可孚医疗 (Kefu Medical) and 翔宇医疗 (Xiangyu Medical) decreased over 5% [1] - 狄耐克 (Dinaike) and 伟思医疗 (Weisi Medical) saw declines greater than 4% [1] Group 2: Company Announcements - Multiple BCI concept stocks issued announcements indicating a cooling off in the market [1] - 航天长峰 (Aerospace Changfeng) stated that the company has not actually engaged in BCI-related business [1] - 伟思医疗 (Weisi Medical) mentioned that new products in the BCI field are still in the early stages of market cultivation [1]

Group 1: Report Investment Ratings - The investment rating for the stock index is "volatile", and for the treasury bond is "relatively strong" [1] Group 2: Core Views - The market showed an upward trend with the Shanghai Composite Index rising above 4000 points and the ChiNext Index rising nearly 3%. The CSI A500 index rose over 2%, reaching a new high since January 2022. The A500ETF had significant net subscriptions, while the net short positions of the top 5 member units in IF increased. The relevant funds may not have significant net outflows after the New Year. In the short - term, the stock index is expected to remain within the oscillation range formed since October. The cumulative year - on - year revenue growth rate of the constituent stocks of the CSI 1000 in the third quarter was about 2.6%, which supports the current valuation and reduces the risk of liquidity. The spring rally may not be as intense as in previous years [1] - The main contracts of treasury bonds declined on Tuesday. The central bank conducted 16.2 billion yuan of 7 - day reverse repurchases, with a net withdrawal of 296.3 billion yuan. The short - term money market is reasonably abundant, which is the biggest support for the bond market, but the stable economy, rising inflation, and cautious attitude towards interest rate cuts pose certain constraints. The bond market is expected to remain range - bound in the short term [1][2] Group 3: Daily Price Changes Stock Index Futures | Variety | 2026 - 01 - 06 Price | 2026 - 01 - 05 Price | Change | Change Rate | | --- | --- | --- | --- | --- | | IH | 3,161.8 | 3,098.8 | 63.0 | 2.03% | | IF | 4,778.0 | 4,697.0 | 81.0 | 1.72% | | IC | 7,786.4 | 7,596.0 | 190.4 | 2.51% | | IM | 7,762.4 | 7,639.0 | 123.4 | 1.62% | [3] Stock Indexes | Variety | 2026 - 01 - 06 Price | 2026 - 01 - 05 Price | Change | Change Rate | | --- | --- | --- | --- | --- | | Shanghai Composite 50 | 3,158.8 | 3,099.7 | 59.0 | 1.90% | | CSI 300 | 4,790.7 | 4,717.7 | 72.9 | 1.55% | | CSI 500 | 7,814.1 | 7,651.2 | 162.9 | 2.13% | | CSI 1000 | 7,864.9 | 7,753.9 | 111.0 | 1.43% | [3] Treasury Bond Futures | Variety | 2026 - 01 - 06 Price | 2026 - 01 - 05 Price | Change | Change Rate | | --- | --- | --- | --- | --- | | TS | 102.37 | 102.41 | - 0.048 | - 0.05% | | TF | 105.57 | 105.71 | - 0.135 | - 0.13% | | T | 107.70 | 107.86 | - 0.155 | - 0.14% | | TL | 110.93 | 111.32 | - 0.39 | - 0.35% | [3] Group 4: Market News - On January 6, the Shanghai Composite Index had 13 consecutive positive days, reaching a ten - year high, with a 1.5% increase. The Shenzhen Component Index rose 1.4%, and the ChiNext Index rose 0.75%. The trading volume of the Shanghai and Shenzhen stock markets was 2.81 trillion yuan, an increase of 260.2 billion yuan from the previous trading day. The brain - computer interface sector had a daily limit surge, and sectors such as insurance, securities, and non - ferrous metals were also strong [4] - From 2024 to 2025, China achieved 18.3 million units of automobile trade - ins, with new energy vehicles accounting for nearly 60%, and 192 million units of home appliance trade - ins, with first - level energy - efficiency (water - efficiency) products accounting for over 90%. The trade - in policy drove consumer sales of 3.92 trillion yuan, benefiting 494 million consumers [4] Group 5: Chart Analysis Stock Index Futures - The report provides charts of the trends of IH, IF, IM, IC main contracts, and their respective monthly basis trends [5][6][7] Treasury Bond Futures - The report provides charts of the trends of treasury bond futures main contracts, treasury bond spot yields, basis of different - term treasury bond futures, inter - period spreads of different - term treasury bond futures, cross - variety spreads, and money market rates [12][13][14] Exchange Rates - The report provides charts of the central parity rates of the US dollar, euro against the RMB, forward exchange rates of the US dollar and euro against the RMB, US dollar index, euro - US dollar exchange rate, pound - US dollar exchange rate, and US dollar - yen exchange rate [21][22][23]

新华财经北京1月7日电（丁晶、董道勇）新年伊始，脑机接口概念股集体"沸腾"，近20只个股连续两个交易日涨停。板块"开门红"缘 于市场对脑机接口巨大潜在需求、产业化进展提速及国家战略支持的叠加效应。 值得注意的是，新华财经数据显示，2026年1月5日该板块主力净流入29亿元，而6日主力资金开始净流出，规模近20亿元，但创新医 疗、爱朋医疗仍受主力资金追捧，继续保持净流入。分析认为，脑机接口行业正迎来"技术与商业化共振"的时刻，2026年脑机接口商 业化进程有望加速，并从医疗刚需向AI应用、机器人等多领域渗透。 长期来看，技术与合规双壁垒及业务联动长期看好头部企业形成技术与合规双壁垒，技术上具备核心专利、领先的研发能力，合规上 符合医疗行业严格的监管要求，如通过国家药监局的行业标准认证等。此外，关注传统业务与脑机接口业务具备联动性的企业，这类 企业可借助原有资源加速脑机接口业务的发展，同时脑机接口业务也能为传统业务带来新的增长极。 对于脑机接口加速"接入"现实，需要关注哪些细分领域？ 国信证券陈曦炳团队指出， 这是一个从0到1的增量市场。短期内，市场情绪受Neuralink量产预期和国内政策利好驱动，具备高爆发 ...

Group 1 - The A-share market has seen a significant pullback in brain-computer interface (BCI) concept stocks, with notable declines in companies such as Mailland and Entropy Technology, which fell over 10% [1] - Several BCI concept stocks have issued announcements indicating a cooling off, with Aerospace Changfeng stating that it has not actually engaged in BCI-related business [1] - Weisi Medical mentioned that its new products in the BCI field are still in the early stages of market cultivation [1] Group 2 - Specific stock performance includes Mailland down 10.68% with a market cap of 5.468 billion, Entropy Technology down 10.13% with a market cap of 10.1 billion, and Chengyi Tong down 7.55% with a market cap of 6.985 billion [2] - Other notable declines include Leedick down 7.14%, Botao Biological down 6.37%, and Aipeng Medical down 6.38% [2] - The overall trend shows that many BCI-related stocks are experiencing a downturn, with declines ranging from 4.33% to 10.68% across various companies [2]

Core Insights - The brain-computer interface (BCI) sector is gaining significant attention, with multiple listed companies responding to the growing interest in this technology [1][4]. Company Responses - Companies such as Xiangyu Medical and Mailland have reported advancements in their BCI projects, with Xiangyu Medical aiming to enter over 1,000 top-tier hospitals in China and Mailland expecting to obtain its first BCI medical device registration certificate by Q1 2026 [5][6]. - Chengdu Huayi and Yingjixin have highlighted their roles in the BCI hardware segment, focusing on signal processing components essential for BCI performance [6][7]. Strategic Collaborations - Yijia is exploring the integration of BCI technology with embodied intelligence robotics, having signed a strategic cooperation agreement with Mailland to develop applications in smart healthcare [7]. - Yahui Long has announced a strategic partnership with Shenzhen Brain Chain Technology to enhance clinical applications and market expansion of BCI technologies [8]. Investment and Market Potential - Strong Brain Technology has recently secured approximately 2 billion yuan in funding, positioning itself as a major player in the BCI field, second only to Neuralink [8]. - The global BCI market is projected to reach approximately $12.4 billion by 2034, with a CAGR of 17% from 2025 to 2034, indicating substantial growth potential [9]. Industry Outlook - The BCI industry is expected to experience significant development opportunities driven by technological innovations, policy support, and capital investments, with promising prospects in healthcare and consumer markets [10].

Core Viewpoint - The A-share market has achieved significant milestones, with the Shanghai Composite Index closing at 4083.67 points, marking a ten-year high and a record 13 consecutive days of gains, indicating strong investor sentiment and a potential shift towards a balanced bull market in 2026 [1][2]. Market Performance - On January 6, all three major A-share indices rose, with the Shanghai Composite Index up by 1.50%, surpassing last year's high and reaching a ten-year peak [2]. - The market saw a surge in trading volume, reaching 2.83 trillion yuan, reflecting heightened investor enthusiasm [1]. - Notable sectors included brain-computer interfaces and commercial aerospace, with significant stock price increases and multiple stocks hitting their daily limit [2]. Fund Inflows - There is a strong expectation for capital inflows into the market, particularly from insurance and financing sectors, which are seen as core support for the current market rally [5]. - As of January 5, 2026, the financing balance reached a historical high of 2.54 trillion yuan, indicating robust market participation [5]. - Insurance funds have also seen substantial growth, with stock and fund allocations increasing by 1.49 trillion yuan since the beginning of the year [5]. Institutional Analysis - Analysts suggest that the current market dynamics are shifting from valuation-driven to profit-driven growth, with a more balanced market style expected [6][7]. - The ongoing economic recovery in China, supported by positive PMI data and industrial growth, provides a solid foundation for the stock market [7]. - Institutions recommend a balanced investment strategy, focusing on sectors like technology, consumer recovery, and high-dividend stocks [8][10]. Investment Strategies - Investment firms are advocating for a diversified approach, emphasizing sectors such as AI, semiconductor, and cyclical assets like metals and chemicals [8][10]. - There is a consensus on avoiding short-term speculation and focusing on long-term value in industries poised for growth [10]. - The recommendation includes a "barbell strategy," targeting both growth sectors and defensive assets to mitigate risks [8].